Vaccine Development Targeting Outer Membrane Proteins of Superbugs

Superbugs are an alarming problem that the medical community is facing nowadays. These bacteria have developed a high level of resistance to most antibiotics, posing a significant threat to public health. One potential strategy for tackling the issue of superbugs is to develop vaccines that specifically target the outer membrane proteins (OMPs) that are essential for the bacteria's survival. They represent an attractive target for vaccine development.

Ace Therapeutics is a company that has extensive experience in the development of vaccines and can help teams in the development of new superbug therapies.

Targeting OMPs of Superbugs

The outer membrane proteins, commonly referred to as OMPs, are of paramount importance in maintaining the structural integrity of the cell wall in gram-negative bacteria. One of the most striking features of OMPs is their high conservation across various bacterial strains, rendering them particularly appealing targets for the development of vaccines. Their multifaceted roles in cellular homeostasis, coupled with their potential as immunogenic epitopes, make them an excellent choice for therapeutic interventions against a broad spectrum of bacterial pathogens.

Major OMPs in Acinetobacter baumannii.Fig. 1 Major OMPs in Acinetobacter baumannii. (Uppalapati S R, et al., 2020)

Our Vaccine Development Services

We specialize in the development of vaccines that target OMPs of superbugs. Our elite team of proficient and highly skilled experts possess extensive knowledge and proficiency in the domains of bacterial genomics, immunology, and vaccine development. We establish close collaboration with our esteemed clients to identify and pinpoint the OMPs that hold the most potential as effective vaccine targets.

Our approach to vaccine development involves several common techniques.

  • Bioinformatics tools. To identify potential OMP targets based on their conservation across different strains of bacteria and their importance in bacterial survival.
  • Molecular biology techniques. To clone and express the OMPs in a recombinant form that is suitable for vaccine development.
  • Recombinant protein technology. To use recombinant OMPs to immunize animals and measure their immune responses.
  • A variety of techniques to assess the efficacy of the vaccine, including enzyme-linked immunosorbent assay (ELISA), western blotting, and flow cytometry.

Potential Targets Available

The intricate world of vaccine development against superbugs is replete with numerous potential OMP targets that could be used. Porins, which are OMPs that effectively modulate the influx and efflux of small molecules, appear to be among the most promising targets. Another OMP target of keen interest is the lipopolysaccharide (LPS) layer.

Several OMPs have been identified as potential vaccine targets, including,

  • OMPs from Acinetobacter baumannii
  • OMPs from Pseudomonas aeruginosa
  • OMPs from Klebsiella pneumoniae

Our Advantages

We have several advantages that set us apart from other vaccine development companies.

  • Deep understanding of bacterial genomics and immunology.
  • State-of-the-art techniques for vaccine development.
  • Work closely with our clients to develop customized solutions that meet their specific needs.

The development of vaccines that target OMPs of superbugs represents a promising strategy for combating antibiotic-resistant bacteria. Ace Therapeutics specialize in the development of these vaccines and offer a range of services to help our clients meet their needs. Contact us today to learn more about how we can help you develop an effective vaccine against superbugs.


  1. Uppalapati S R, et al. The outer membrane proteins OmpA, CarO, and OprD of Acinetobacter baumannii confer a two-pronged defense in facilitating its success as a potent human pathogen. Frontiers in microbiology, 2020, 11: 589234.
  2. Russo T A, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infection and Immunity, 2016, 84(10): 31-16.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.